# US 2024/0093202 A1 · Suppression-Replacement Gene Therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0093202 A1
- Document ID: US20240093202A1
- Status: Published application
- Kind: A1
- Application number: 18/270,014
- Filed: 2021-12-30
- Published: 2024-03-21
- Earliest claimed: 2020-12-30
- Assignees: Mayo Foundation for Medical Education and Research
- Applicants: Mayo Foundation for Medical Education and Research
- Inventors: Michael J. ACKERMAN; Steven M. DOTZLER; William GENDRON; Sahej BAINS; Changsung John KIM; David J. TESTER
- Web page: https://patentgrep.com/patent/US20240093202A1

## CPC

- C12N 15/1138: {against receptors or cell surface proteins}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C12N 15/86: Viral vectors
- A01K 2217/054: inducing loss of function
- A01K 2227/107: Rabbit
- A01K 2267/0375: Animal model for cardiovascular diseases
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2320/31: Combination therapy
- C12N 2320/34: Allele or polymorphism specific uses
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2840/203: having an IRES
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

Methods and materials for treating a mammal having a congenital disease (e.g., a congenital heart disease such as congenital long QT syndrome) are provided herein. For example, this document provides methods and materials for generating and using nucleic acids to treat a mammal having a congenital disease, where the nucleic acids can suppress expression of mutant disease-related alleles in the mammal while providing a replacement cDNA that does not contain the disease-related mutation(s).

## Claims

### Claim 1

A nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNQ1 polypeptide within a cell and suppressing expression of said endogenous KCNQ1 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNQ1 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNQ1 polypeptide from said second nucleotide sequence within said cell.

### Claim 2 (depends on 1)

The nucleic acid construct of claim 1, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:36, and wherein said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 3 (depends on 1)

The nucleic acid construct of claim 1, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:36 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 4 (depends on 1, 2, 3)

The nucleic acid construct of any one of claims 1 to 3, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 5 (depends on 4)

The nucleic acid construct of claim 4, wherein said first and second promoters are the same.

### Claim 6 (depends on 4)

The nucleic acid construct of claim 4, wherein said first and second promoters are different.

### Claim 7 (depends on 6)

The nucleic acid construct of claim 6, wherein said first promoter is a U6 promoter and said second promoter is a cytomegalovirus immediate-early (CMV) promoter.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid construct of any one of claims 1 to 7, further comprising a nucleotide sequence encoding a reporter.

### Claim 9 (depends on 8)

The nucleic acid construct of claim 8, wherein said reporter is a fluorescent polypeptide.

### Claim 10 (depends on 8, 9)

The nucleic acid construct of claim 8 or claim 9, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an internal ribozyme entry sequence (IRES) or P2A self-cleaving peptide sequence.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid construct of any one of claims 1 to 10, wherein said nucleic acid construct is within a viral vector.

### Claim 12 (depends on 11)

The nucleic acid construct of claim 11, wherein said viral vector is an adeno-associated virus (AAV) vector.

### Claim 13 (depends on 12)

The nucleic acid construct of claim 12, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleic acid construct of any one of claims 1 to 13, wherein said cell is a cardiomyocyte.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

A virus particle comprising the nucleic acid construct of any one of claims 1 to 14.

### Claim 16

A method for treating a mammal having a congenital cardiac disease, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNQ1 polypeptide within a cell of said mammal and suppressing expression of said endogenous KCNQ1 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNQ1 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNQ1 polypeptide from said second nucleotide sequence within said cell.

### Claim 17 (depends on 16)

The method of claim 16, wherein said congenital cardiac disease is long QT syndrome (LQTS) or short QT syndrome (SQTS).

### Claim 18 (depends on 16)

The method of claim 16, wherein said congenital cardiac disease is LQT1.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16 to 18, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:36, and wherein said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 20 (depends on 16, 17, 18)

The method of any one of claims 16 to 18, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:36 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 21 (depends on 16, 17, 18, 19, 20)

The method of any one of claims 16 to 20, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 22 (depends on 21)

The method of claim 21, wherein said first and second promoters are the same.

### Claim 23 (depends on 21)

The method of claim 21, wherein said first and second promoters are different.

### Claim 24 (depends on 21)

The method of claim 21, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 25 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 16 to 24, wherein said nucleic acid construct further comprises a nucleotide sequence encoding a reporter.

### Claim 26 (depends on 25)

The method of claim 25, wherein said reporter is a fluorescent polypeptide.

### Claim 27 (depends on 25, 26)

The method of claim 25 or claim 26, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an IRES.

### Claim 28 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 16 to 27, wherein said nucleic acid construct is within a viral vector.

### Claim 29 (depends on 28)

The method of claim 28, wherein said viral vector is an AAV vector.

### Claim 30 (depends on 29)

The method of claim 29, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 31 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 16 to 30, wherein said cell is a cardiomyocyte.

### Claim 32

A method for reducing the action potential duration (APD) in cardiac cells within a mammal, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNQ1 polypeptide within cardiac cells of said mammal and suppressing expression of said endogenous KCNQ1 polypeptide within said cardiac cells, and
(b) a second nucleotide sequence encoding a KCNQ1 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNQ1 polypeptide from said second nucleotide sequence within said cell.

### Claim 33 (depends on 32)

The method of claim 32, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:36, and wherein said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 34 (depends on 32)

The method of claim 32, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:36 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32 to 34, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 36 (depends on 35)

The method of claim 35, wherein said first and second promoters are the same.

### Claim 37 (depends on 35)

The method of claim 35, wherein said first and second promoters are different.

### Claim 38 (depends on 37)

The method of claim 37, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The method of any one of claims 32 to 38, wherein said nucleic acid construct is within a viral vector.

### Claim 40 (depends on 39)

The method of claim 39, wherein said viral vector is an AAV vector.

### Claim 41 (depends on 40)

The method of claim 40, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 42

A method for reducing one or more symptoms of LQTS in a mammal, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNQ1 polypeptide within a cell of said mammal and suppressing expression of said endogenous KCNQ1 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNQ1 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNQ1 polypeptide from said second nucleotide sequence within said cell.

### Claim 43 (depends on 42)

The method of claim 42, wherein said LQTS is LQT1.

### Claim 44 (depends on 42, 43)

The method of claim 42 or claim 43, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, or SEQ ID NO:36, and wherein said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 45 (depends on 42, 43)

The method of claim 42 or claim 43, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:36 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:9.

### Claim 46 (depends on 42, 43, 44, 45)

The method of any one of claims 42 to 45, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 47 (depends on 46)

The method of claim 46, wherein said first and second promoters are the same.

### Claim 48 (depends on 46)

The method of claim 46, wherein said first and second promoters are different.

### Claim 49 (depends on 48)

The method of claim 48, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 50 (depends on 42, 43, 44, 45, 46, 47, 48, 49)

The method of any one of claims 42 to 49, wherein said nucleic acid construct is within a viral vector.

### Claim 51 (depends on 50)

The method of claim 50, wherein said viral vector is an AAV vector.

### Claim 52 (depends on 51)

The method of claim 51, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 53 (depends on 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 42 to 52, wherein said cell is a cardiomyocyte.

### Claim 54

A nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNH2 polypeptide within a cell and suppressing expression of said endogenous KCNH2 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNH2 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNH2 polypeptide from said second nucleotide sequence within said cell.

### Claim 55 (depends on 54)

The nucleic acid construct of claim 54, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:27 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:29.

### Claim 56 (depends on 54, 55)

The nucleic acid construct of claim 54 or claim 55, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 57 (depends on 56)

The nucleic acid construct of claim 56, wherein said first and second promoters are the same.

### Claim 58 (depends on 56)

The nucleic acid construct of claim 56, wherein said first and second promoters are different.

### Claim 59 (depends on 58)

The nucleic acid construct of claim 58, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 60 (depends on 54, 55, 56, 57, 58, 59)

The nucleic acid construct of any one of claims 54 to 59, further comprising a nucleotide sequence encoding a reporter.

### Claim 61 (depends on 60)

The nucleic acid construct of claim 60, wherein said reporter is a fluorescent polypeptide.

### Claim 62 (depends on 60, 61)

The nucleic acid construct of claim 60 or claim 61, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an IRES or P2A self-cleaving peptide sequence.

### Claim 63 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62)

The nucleic acid construct of any one of claims 54 to 62, wherein said nucleic acid construct is within a viral vector.

### Claim 64 (depends on 63)

The nucleic acid construct of claim 63, wherein said viral vector is an AAV vector.

### Claim 65 (depends on 64)

The nucleic acid construct of claim 64, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 66 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The nucleic acid construct of any one of claims 54 to 65, wherein said cell is a cardiomyocyte.

### Claim 67 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

A virus particle comprising the nucleic acid construct of any one of claims 54 to 66.

### Claim 68

A method for treating a mammal having a congenital cardiac disease, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNH2 polypeptide within a cell of said mammal and suppressing expression of said endogenous KCNH2 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNH2 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNH2 polypeptide from said second nucleotide sequence within said cell.

### Claim 69 (depends on 68)

The method of claim 68, wherein said congenital cardiac disease is LQTS or SQTS.

### Claim 70 (depends on 68)

The method of claim 68, wherein said congenital cardiac disease is LQT2.

### Claim 71 (depends on 68, 69, 70)

The method of any one of claims 68 to 70, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:27 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:29.

### Claim 72 (depends on 68, 69, 70, 71)

The method of any one of claims 68 to 71, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 73 (depends on 72)

The method of claim 72, wherein said first and second promoters are the same.

### Claim 74 (depends on 72)

The method of claim 72, wherein said first and second promoters are different.

### Claim 75 (depends on 74)

The method of claim 74, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 76 (depends on 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 68 to 75, wherein said nucleic acid construct further comprises a nucleotide sequence encoding a reporter.

### Claim 77 (depends on 76)

The method of claim 76, wherein said reporter is a fluorescent polypeptide.

### Claim 78 (depends on 76, 77)

The method of claim 76 or claim 77, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an IRES.

### Claim 79 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 68 to 78, wherein said nucleic acid construct is within a viral vector.

### Claim 80 (depends on 79)

The method of claim 79, wherein said viral vector is an AAV vector.

### Claim 81 (depends on 80)

The method of claim 80, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 82 (depends on 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 68 to 81, wherein said cell is a cardiomyocyte.

### Claim 83

A method for reducing the APD in cardiac cells within a mammal, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNH2 polypeptide within cardiac cells of said mammal and suppressing expression of said endogenous KCNH2 polypeptide within said cardiac cells, and
(b) a second nucleotide sequence encoding a KCNH2 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNH2 polypeptide from said second nucleotide sequence within said cell.

### Claim 84 (depends on 83)

The method of claim 83, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:27 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:29.

### Claim 85 (depends on 83, 84)

The method of claim 83 or claim 84, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 86 (depends on 85)

The method of claim 85, wherein said first and second promoters are the same.

### Claim 87 (depends on 85)

The method of claim 85, wherein said first and second promoters are different.

### Claim 88 (depends on 87)

The method of claim 87, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 89 (depends on 83, 84, 85, 86, 87, 88)

The method of any one of claims 83 to 88, wherein said nucleic acid construct is within a viral vector.

### Claim 90 (depends on 89)

The method of claim 89, wherein said viral vector is an AAV vector.

### Claim 91 (depends on 90)

The method of claim 90, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 92

A method for reducing one or more symptoms of LQTS in a mammal, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding an endogenous KCNH2 polypeptide within a cell of said mammal and suppressing expression of said endogenous KCNH2 polypeptide within said cell, and
(b) a second nucleotide sequence encoding a KCNH2 polypeptide, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said KCNH2 polypeptide from said second nucleotide sequence within said cell.

### Claim 93 (depends on 92)

The method of claim 92, wherein said LQTS is LQT2.

### Claim 94 (depends on 92, 93)

The method of claim 92 or claim 93, wherein said first nucleotide sequence comprises the sequence set forth in SEQ ID NO:27 and said second nucleotide sequence comprises the sequence set forth in SEQ ID NO:29.

### Claim 95 (depends on 92, 93, 94)

The method of any one of claims 92 to 94, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 96 (depends on 95)

The method of claim 95, wherein said first and second promoters are the same.

### Claim 97 (depends on 95)

The method of claim 95, wherein said first and second promoters are different.

### Claim 98 (depends on 97)

The method of claim 97, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 99 (depends on 92, 93, 94, 95, 96, 97, 98)

The method of any one of claims 92 to 98, wherein said nucleic acid construct is within a viral vector.

### Claim 100 (depends on 99)

The method of claim 99, wherein said viral vector is an AAV vector.

### Claim 101 (depends on 100)

The method of claim 100, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 102 (depends on 92, 93, 94, 95, 96, 97, 98, 99, 100, 101)

The method of any one of claims 92 to 101, wherein said cell is a cardiomyocyte.

### Claim 103

A nucleic acid construct for treating a congenital heart disease caused by an endogenous cardiac polypeptide containing one or more mutations causative of said congenital heart disease, wherein said construct comprises:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding said endogenous cardiac polypeptide within a cell and suppressing expression of said endogenous cardiac polypeptide within said cell, and
(b) a second nucleotide sequence encoding a replacement version of said endogenous cardiac polypeptide that lacks said one or more mutations causative of said congenital heart disease, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said replacement version of said endogenous cardiac polypeptide that lacks said one or more mutations causative of said congenital heart disease from said second nucleotide sequence within said cell.

### Claim 104 (depends on 103)

The nucleic acid construct of claim 103, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 105 (depends on 104)

The nucleic acid construct of claim 104, wherein said first and second promoters are the same.

### Claim 106 (depends on 104)

The nucleic acid construct of claim 104, wherein said first and second promoters are different.

### Claim 107 (depends on 106)

The nucleic acid construct of claim 106, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 108 (depends on 103, 104, 105, 106, 107)

The nucleic acid construct of any one of claims 103 to 107, further comprising a nucleotide sequence encoding a reporter.

### Claim 109 (depends on 108)

The nucleic acid construct of claim 108, wherein said reporter is a fluorescent polypeptide.

### Claim 110 (depends on 108, 109)

The nucleic acid construct of claim 108 or claim 109, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an internal ribozyme entry sequence (IRES) or P2A self-cleaving peptide sequence.

### Claim 111 (depends on 103, 104, 105, 106, 107, 108, 109, 110)

The nucleic acid construct of any one of claims 103 to 110, wherein said nucleic acid construct is within a viral vector.

### Claim 112 (depends on 111)

The nucleic acid construct of claim 111, wherein said viral vector is an AAV vector.

### Claim 113 (depends on 112)

The nucleic acid construct of claim 112, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 114 (depends on 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113)

The nucleic acid construct of any one of claims 103 to 113, wherein said cell is a cardiomyocyte.

### Claim 115 (depends on 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114)

A virus particle comprising the nucleic acid construct of any one of claims 103 to 114.

### Claim 116

A method for treating a mammal having a congenital cardiac disease, said method comprising administering to said mammal a nucleic acid construct comprising:
(a) a first nucleotide sequence encoding an RNAi molecule capable of hybridizing to a target sequence encoding said endogenous cardiac polypeptide within a cell and suppressing expression of said endogenous cardiac polypeptide within said cell, and
(b) a second nucleotide sequence encoding a replacement version of said endogenous cardiac polypeptide that lacks said one or more mutations causative of said congenital heart disease, wherein said second nucleotide sequence comprises a target sequence identical to said target sequence of said first nucleotide sequence with the exception that said target sequence of said second nucleotide sequence comprises 1 to 13 wobble position variants as compared to said target sequence of said first nucleotide sequence, and wherein said RNAi molecule does not suppress expression of said replacement version of said endogenous cardiac polypeptide that lacks said one or more mutations causative of said congenital heart disease from said second nucleotide sequence within said cell.

### Claim 117 (depends on 116)

The method of claim 116, wherein said first nucleotide sequence is operably linked to a first promoter and said second nucleotide sequence is operably linked to a second promoter.

### Claim 118 (depends on 117)

The method of claim 117, wherein said first and second promoters are the same.

### Claim 119 (depends on 117)

The method of claim 117, wherein said first and second promoters are different.

### Claim 120 (depends on 119)

The method of claim 119, wherein said first promoter is a U6 promoter and said second promoter is a CMV promoter.

### Claim 121 (depends on 116, 117, 118, 119, 120)

The method of any one of claims 116 to 120, wherein said nucleic acid construct further comprises a nucleotide sequence encoding a reporter.

### Claim 122 (depends on 121)

The method of claim 121, wherein said reporter is a fluorescent polypeptide.

### Claim 123 (depends on 121, 122)

The method of claim 121 or claim 122, wherein said nucleotide sequence encoding said reporter is downstream of said second nucleotide sequence encoding said cDNA, and is separated from said second nucleotide sequence by an IRES.

### Claim 124 (depends on 116, 117, 118, 119, 120, 121, 122, 123)

The method of any one of claims 116 to 123 wherein said nucleic acid construct is within a viral vector.

### Claim 125 (depends on 124)

The method of claim 124, wherein said viral vector is an AAV vector.

### Claim 126 (depends on 125)

The method of claim 125, wherein said AAV vector is an AAV serotype 9 vector or an AAV2/9 vector.

### Claim 127 (depends on 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126)

The method of any one of claims 116 to 126, wherein said cell is a cardiomyocyte.
